Patents Assigned to Yeshiva University
  • 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE
    Publication number: 20120157479
    Abstract: The present invention relates to 3-hydroxypyrrolidine compounds of the general formula (I) which are inhibitors of 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.
    Type: Application
    Filed: July 16, 2010
    Publication date: June 21, 2012
    Applicants: INDUSTRIAL RESEARCH LIMITED, ALBERT EINSTEIN COLLEGE OF YESHIVA UNIVERSITY
    Inventors: Gary Brian Evans, Alistair Ian Longshaw, Vern L. Schramm, Peter Charles Tyler
  • Anti-peptide antibodies that cross react with protective antigen of and uses thereof
    Patent number: 8187611
    Abstract: The present invention provides a purified peptide comprising at least one of the sequences LKQKSSNSRKKRSTS (SEQ ID NO:1), or VKNKRTFLSPWISNI (SEQ ID NO:2) as well as a vaccine, a method to protect or treat an animal from anthrax toxin, a method of making a vaccine and the use of the peptide. The present invention also provides a monoclonal antibody that specifically binds to a peptide sequence comprising at least one of the following peptide sequences: LKQKSSNSRKKRSTS (SEQ ID NO:1), or VKNKRTFLSPWISNI (SEQ ID NO:2) as well as a method to protect or treat an animal from anthrax toxin, a method of making a vaccine, a pharmaceutical composition, a method of making a pharmaceutical composition, and the use of the monoclonal antibody.
    Type: Grant
    Filed: October 5, 2010
    Date of Patent: May 29, 2012
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Nareen Abboud, Arturo Casadevall
  • METHODS FOR DETERMINING AGENTS THAT TREAT OR PREVENT OBESITY AND/OR OBESITY RELATED DISEASES AND METHODS FOR TREATMENT THEREWITH
    Publication number: 20120128690
    Abstract: The present invention provides methods for determining a putative agent that treats or prevent obesity and/or obesity related diseases comprising contacting cells with the putative agent and measuring the activity and/or level of Maf1 and/or the activity and/or level of KIAA1875. The present invention also provides the agent identified by the methods herein and methods of treating or preventing obesity and/or obesity related diseases in a subject comprising administering to the subject a therapeutically effective amount of an agent that inhibits or downregulates Maf1 and/or activates or upregulates KIAA1875.
    Type: Application
    Filed: November 17, 2011
    Publication date: May 24, 2012
    Applicants: University of Lausanne, Albert Einstein College of Medicine of Yeshiva University
    Inventors: Ian M. Willis, Nouria Hernandez, Wassim Hodroj
  • Fused pyrimidines as inhibitors of nucleoside phosphorylases and nucleosidases
    Patent number: 8173662
    Abstract: The present invention relates to compounds of the general formula (I) which are inhibitors of purine muclioside phosphorylases (PNP), purine phosphoribosyltransferases (PPRT), 5?-methylthioadenosine phosphorylases (MTAP), 5?-methylthioadenosine mucliosidases (MTAN) and/or nucleoside hydrolases (NH). The invention also relates to the use of these compounds in the treatment of diseases and infections including cancer, bacterial infections, protozoal infections, and T-cell mediated disease and to pharmaceutical compositions containing the compounds.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: May 8, 2012
    Assignees: Industrial Research Limited, Albert Einstein College of Medicine of Yeshiva University
    Inventors: Gary Brian Evans, Richard Hubert Furneaux, Dirk Henning Lenz, Vern L. Schramm, Peter Charles Tyler, Olga Vladimirovna Zubkova
  • Inhibition of Skp2-cyclin a interaction
    Patent number: 8173604
    Abstract: Methods of killing a cancer cell are provided. Also provided are methods of treating a subject having a cancer. Additionally, compounds are provided that comprise a peptide from about 18 to about 100 amino acids or peptidomimetics comprising the sequence of SEQ ID NO:1. Additionally provided are methods of screening an agent for the ability to kill a cancer cell.
    Type: Grant
    Filed: May 23, 2007
    Date of Patent: May 8, 2012
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Liang Zhu, Peng Ji
  • Regulation of lipid droplet formation by modulation of FIT1 and FIT2 and uses thereof
    Patent number: 8129121
    Abstract: This invention provides methods of regulating fat storage in tissue by modulating the levels of Fibrate Induced Transcript 1 (FIT1) and/or Fibrate Induced Transcript 2 (FIT2), as well as diagnostic screens for disorders and conditions involving regulation of fat storage in tissue, assays for identifying agents that can regulate fat storage in tissue through modulating the levels of FIT1 and/or FIT2, and genetically altered mammals in which expression of FIT1 and/or FIT2 is altered in one or more tissue.
    Type: Grant
    Filed: January 8, 2008
    Date of Patent: March 6, 2012
    Assignees: Albert Einstein College of Medicine of Yeshiva University, The Trustees of Columbia University in the City of New York
    Inventor: David L. Silver
  • Multi-microRNA methods and compositions
    Patent number: 8114982
    Abstract: Provided are DNAs comprising a polynucleotide that encodes at least a first modified miR-30 precursor and a second modified miR-30 precursor. Also provided are vectors comprising the the DNAs, where the vector can replicate in a host cell. Additionally, specific lentiviral vectors comprising the above-described DNA are provided, as are methods of inhibiting expression of a target gene in a eukaryotic cell.
    Type: Grant
    Filed: November 28, 2007
    Date of Patent: February 14, 2012
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Liang Zhu, Daqian Sun
  • METHODS OF EVALUATING PATIENTS
    Publication number: 20120020970
    Abstract: Methods of treating patients and evaluating patients for disease stage and/or severity are disclosed.
    Type: Application
    Filed: September 22, 2011
    Publication date: January 26, 2012
    Applicants: Albert Einstein College of Medicine of Yeshiva University, Biogen Idec MA Inc.
    Inventors: Linda C. Burkly, Jennifer Michaelson, Chaim Putterman
  • Mycobacterial SecA2 mutants
    Patent number: 8101191
    Abstract: Provided are mycobacteria comprising (a) a mutation that is not in a SecA2 gene that attenuates the virulence of the mycobacteria in a mammalian host, and (b) a mutation in a SecA2 gene that eliminates SecA2 activity. Also provided are mycobacteria that comprise a mutation in a SecA2 gene that eliminates SecA2 activity, where the mycobacteria are not Mycobacterium tuberculosis or Mycobacterium smegmatis. Additionally provided are methods of inducing an immune response in a mammal and methods of inducing an immune response to a pathogenic mycobacterium in a human using the above mycobacterial mutants.
    Type: Grant
    Filed: January 11, 2007
    Date of Patent: January 24, 2012
    Assignees: Albert Einstein College of Medicine of Yeshiva University, The University of North Carolina at Chapel Hill
    Inventors: William R. Jacobs, Jr., Steven A. Porcelli, Miriam Braunstein
  • Use of mycrobacterial vaccines in CD4 or CD8 lymphocyte-deficient mammals
    Patent number: 8084041
    Abstract: Methods of treating a mammal that is deficient in CD4+ and/or CD8+ lymphocytes are provided. The methods comprise inoculating the mammal with an attenuated mycobacterium in the M. tuberculosis complex. In these methods, the mycobacterium comprises two deletions, wherein a virulent mycobacterium in the M. tuberculosis complex having either deletion exhibits attenuated virulence. Use of these mycobacteria for the manufacture of a medicament for the treatment of mammals deficient in CD4+ and/or CD8+ lymphocytes is also provided.
    Type: Grant
    Filed: January 23, 2004
    Date of Patent: December 27, 2011
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: William R. Jacobs, Jr., Tsungda Hsu, Vasan Sambandamurthy, Sheldon Morris, Stoyan Bardarov, Svetoslav Bardarov, legal representative
  • Caged ligands and uses thereof
    Patent number: 8076318
    Abstract: Provided are caged compounds comprising a ligand that specifically reacts with a receptor not naturally present in mammals. The cage is released from the ligand upon illumination of the compound with light. Also provided are cells transfected with a gene of interest and a gene encoding a receptor, the gene of interest operably linked to a genetic element capable of being induced by the receptor when bound to a ligand, and the receptor not naturally present in the species of the cell. The cells also comprise a caged ligand of the receptor. Additionally provided are methods of inducing a gene of interest in the above cells. Also provided are methods of repressing a gene of interest in a cell using caged ligands of receptors. Methods are additionally provided for inducing elimination of a target sequence in a cell of a species, using a caged ligand and a recombinase.
    Type: Grant
    Filed: October 22, 2003
    Date of Patent: December 13, 2011
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: David S. Lawrence, Richard G. Pestell, Christopher Albanese
  • Protein tyrosine phosphatase substrate-trapping double mutant and uses thereof
    Patent number: 8071348
    Abstract: The present invention provides protein tyrosine phosphatases (PTP) in which the invariant aspartate residue and the invariant glutamine residue are each replaced with a replacement amino acid residue, wherein the replacement residues together cause a reduction in catalytic rate (kcat) of the enzyme and an increase in substrate-binding affinity (Kd) of the enzyme. The present invention further provides methods for identifying a substrate of a PTP. Also provided are kits for identifying a substrate of a PTP. Additionally, the present invention provides methods for identifying an agent that alters interaction between a PTP and a substrate of the PTP. The invention also provides methods for reducing the activity of a substrate of a PTP.
    Type: Grant
    Filed: January 10, 2003
    Date of Patent: December 6, 2011
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Zhong-Yin Zhang, Laiping Xie, Yan-Ling Zhang
  • Uses of pegylated albumin
    Patent number: 8071546
    Abstract: The present invention is directed to uses of PEGylated albumins which include methods of treating reduced functional capillary density, reduced blood volume, septic shock and cardiac arrhythmia in a subject, which comprise administering to the subject a therapeutically effective amount of a PEGylated albumin.
    Type: Grant
    Filed: June 9, 2006
    Date of Patent: December 6, 2011
    Assignees: La Jolla Bioengineering Institute, Albert Einstein College of Medicine of Yeshiva University
    Inventors: Pedro Cabrales, Amy Tsai, Seetharama A. Acharya, Belur N. Manjula
  • Measurement of soluble Tweak levels for evaluation of lupus patients
    Patent number: 8048635
    Abstract: Methods of treating patients and evaluating patients for disease stage and/or severity are disclosed.
    Type: Grant
    Filed: December 10, 2007
    Date of Patent: November 1, 2011
    Assignees: Biogen Idec MA Inc., Albert Einstein College of Medicine of Yeshiva University
    Inventors: Linda C. Burkly, Jennifer Michaelson, Chaim Putterman
  • Surface coil arrays for simultaneous reception and transmission with a volume coil and uses thereof
    Patent number: 8030926
    Abstract: This invention provides arrays of counter rotating current surface coils for simultaneous reception and transmission with a volume coil for improved signal-to-noise ratio and radio frequency field homogeneity for in particular high-field (4-8 T) imaging of deep body regions, such as central brain structures.
    Type: Grant
    Filed: March 1, 2007
    Date of Patent: October 4, 2011
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Nikolai I. Avdievich, Hoby P. Hetherington
  • Ceramide derivatives as modulators of immunity and autoimmunity
    Patent number: 8022043
    Abstract: ?-Galactosylceramides and glycosylceramides (“ceramide-like glycolipids”) that modulate NK T cells. The ceramide-like glycolipids vary in the cytokines induced in NK T cells and vary in the antigen-presenting cells that are capable of efficiently presenting the compounds to NK T cells. Pharmaceutical compositions of the ceramide-like glycolipids are provided, as are pharmaceutical compositions of the ceramide-like glycolipids combined with dendritic cells. Methods utilizing the ceramide-like glycolipids in vaccines, to activate NK T cells, to stimulate the immune system, and to treat mammals are also provided. The invention also provides methods of evaluating a compound for its ability to activate an NK T cell in the presence of a cell expressing a CD1d protein.
    Type: Grant
    Filed: April 23, 2007
    Date of Patent: September 20, 2011
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventor: Steven A. Porcelli
  • Inhibition of membrane fusion proteins
    Patent number: 8003332
    Abstract: Methods of inhibiting viral infection of a eukaryotic cell by a target virus having a class II virus fusion protein are provided. Also provided are methods of screening a test compound for the ability to inhibit infection by a virus having a class II viral fusion protein. Additionally provided herewith are aqueous-soluble proteins comprising a portion of a class II viral fusion protein comprising a Domain III of the viral fusion protein.
    Type: Grant
    Filed: May 4, 2006
    Date of Patent: August 23, 2011
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Margaret Kielian, Maofu Liao
  • Mycobacteria expressing HIV-1 and malaria antigens
    Patent number: 7998471
    Abstract: Provided are recombinant mycobacteria expressing an HIV-1 antigen and a malarial antigen. Also provided are Mycobacterium smegmatis expressing an HIV-1 antigen. Further provided are vaccines capable of inducing an immune response in a mammal against HIV-1 and the malarial pathogen. Additionally provided are methods of inducing an immune response in a mammal against HIV-1 and a malarial pathogen. Also provided are methods of inducing an immune response in a mammal against HIV-1. The methods comprise infecting the mammal with any of the above-described mycobacteria.
    Type: Grant
    Filed: January 11, 2006
    Date of Patent: August 16, 2011
    Assignees: Albert Einstein College of Medicine of Yeshiva University, Beth Israel Deaconess Medical Center, Inc., Duke University
    Inventors: William R. Jacobs, Jr., Norman L. Letvin, Mark Cayabyab, Barton F. Haynes, Hua-Xin Liao, Jae-Sung Yu, Avi-Hai Hovav
  • SIR2 REGULATION
    Publication number: 20110178102
    Abstract: Compounds are disclosed which inhibit SIR2 base exchange more than deacetylation, thus enhancing SIR2 deacetylation activity. Methods of using the compounds for enhancing SIR2 deacetylation activity and increasing longevity of an organism are also disclosed. Methods for screening for compounds that enhance SIR2 deacetylation activity and increase longevity of an organism are additionally disclosed.
    Type: Application
    Filed: June 30, 2004
    Publication date: July 21, 2011
    Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
    Inventors: Vern L Schramm, Anthony A. Suave
  • Anti-peptide antibodies that cross react with protective antigen of bacillus anthracis and uses thereof
    Publication number: 20110171223
    Abstract: The present invention provides a purified peptide comprising at least one of the sequences LKQKSSNSRKKRSTS (SEQ ID NO:1), or VKNKRTFLSPWISNI (SEQ ID NO:2) as well as a vaccine, a method to protect or treat an animal from anthrax toxin, a method of making a vaccine and the use of the peptide. The present invention also provides a monoclonal antibody that specifically binds to a peptide sequence comprising at least one of the following peptide sequences: LKQKSSNSRKKRSTS (SEQ ID NO:1), or VKNKRTFLSPWISNI (SEQ ID NO:2) as well as a method to protect or treat an animal from anthrax toxin, a method of making a vaccine, a pharmaceutical composition, a method of making a pharmaceutical composition, and the use of the monoclonal antibody.
    Type: Application
    Filed: October 5, 2010
    Publication date: July 14, 2011
    Applicant: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Nareen Abboud, Arturo Casadevall